reports
ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK In...
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced final results from the phase 1 study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or refractory hematologic malignancies at the American Society of Hematology (ASH) 2019 Annual Meeting & Exposition in Orlando, Florida. “The final phase 1 data set confirms the potential utility of ARQ 531 for the treatment of these heavily pretreated CLL patients. We were excited to observe such deep and durabl...
ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ ...
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that final clinical data from the company-sponsored phase 1 study of ARQ 531 will be presented on December 9, 2019 at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The poster presentation will highlight the final data set with respect to ARQ 531’s safety profile, clinical activity and durability across multiple refractory B-cell malignancies, including C481-mutant chronic lymphocytic leukemia (CLL). Presentation Details Title: Final Results of Phase 1, Dose Escala...
ArQule to Participate in the Jefferies London Healthcare Conference on...
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2019 in London, UK. About ArQule ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline c...
ArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC Inte...
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL), today announced new clinical and preclinical data demonstrating the potential of the company’s AKT inhibitor ARQ 751 in treating solid tumors characterized by mutations in the PI3K/AKT/mTOR pathway. The findings were detailed in two poster presentations at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. “Traditional tumor biopsies used to identify tumor mutational status can be burdensome for patients; therefore, using biomarkers such as ctDNA from standard blood sampling would be...
ARQULE INCO. reduces its risk exposure and slightly improves to Neutra...
The independent financial analyst theScreener just allocated a lower risk rating to ARQULE INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 3 out of 4 possible stars. Its market behaviour, however, has slightly improved and can be qualified as moderately risky. theScreener considers that these elements merit an overall rating upgrade to Neutral. As of the analysis date October 25, 2019, the closing price was USD 9.50 and its expected v...
ArQule to Report Third Quarter 2019 Financial Results on October 30, 2...
BURLINGTON, Mass.--(BUSINESS WIRE)-- , Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter of 2019 before the market opens on Wednesday, October 30, 2019. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update. The live webcast can be accessed in the “Investors and Media” section of our website, , under “.” You may also listen to the call by dialing (877) 868-1831 within the U.S. or (914) 495-8595 outside the U.S. and entering the conference ID: 4289763. A replay...
ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC I...
BURLINGTON, Mass.--(BUSINESS WIRE)-- , Inc. (Nasdaq: ARQL) today announced that it will be presenting data on the company’s AKT inhibitor, ARQ 751, in two poster presentations at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held from October 26th to October 30th, 2019 in Boston, Massachusetts. Presentations will detail clinical data demonstrating the correlation between biomarkers and patient response to treatment with ARQ 751 as well as preclinical in vivo and in vitro findings supporting the potential of ARQ 751 in combination with a v...
 ArQule to Present Preclinical Data on Miransertib for the Treatment ...
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting research on the company’s pan-AKT inhibitor, miransertib (ARQ 092), in a poster presentation at the 2019 ASHG Annual Meeting being held from October 15 to October 19, 2019 in Houston, Texas. The presentation will detail results from a preclinical study of miransertib demonstrating its potential for treating PIK3CA-driven vascular malformations. Details on the presentation are as follows: Presentation Title: PgmNr 2702/F: Miransertib (ARQ 092) prevents the formation of PIK3CAH1047R-...
- Jonathan Moreland
WMS ADVANCED DRAINAGE SYSTEMS INC.
TUESQ TUESDAY MORNING CORP.
RVSB RIVERVIEW BANCORP INC.
PGNX PROGENICS PHARMACEUTICALS INC.
PFSW PFSWEB INC
PEI PENNSYLVANIA REAL ESTATE INVESTMENT TRUST
NMFC NEW MOUNTAIN FINANCE CORPORATION
NEWM GANNETT CO. INC.
MCHX MARCHEX INC. CL B
DLY LYONDELLBASELL INDUSTRIES NV
LXRX LEXICON PHARMACEUTICALS INC.
INGN INOGEN INC.
HBIO HARVARD BIOSCIENCE INC.
GPORQ GULFPORT ENERGY CORPORATION
GME GAMESTOP CORP. CLASS A
GDOT GREEN DOT CORPORATION CLASS A
EPC EDGEWELL PERSONAL CARE CO.
COTY COTY INC. CLASS A
CNO CNO FINANCIAL GROUP INC.
CDTX CIDARA THERAPEUTICS
BGGSQ BRIGGS & STRATTON CORPORATION
ARQL ARQULE INC.
ALDX ALDEYRA THERAPEUTICS
AERI AERIE PHARMACEUTICALS INC.
FTEK FUEL TECH
PRU PRUDENTIAL PLC
SAFE SAFESTORE HOLDINGS PLC
MN MANNING & NAPIER
HOME AT HOME GROUP INC.
BASI BIOANALYTICAL SYSTEMS
CSTR CAPSTAR FINANCIAL HOLDINGS
FEIM FREQUENCY ELECTRONICS INC.
COT COTT CORPORATION
ALRN AILERON THERAPEUTICS
CTDH CTD HOLDINGS INC
EXPI EXP WORLD HOLDINGS
CELH CELSIUS HOLDINGS INC.
CTRA ALPHA METALLURGICAL RESOURCES INC.
ABBV ABBVIE INC.
SFIX STITCH FIX CLASS A
ZUO ZUORA
MYND MYND ANALYTICS
DBX DROPBOX INC. CLASS A
DOMO DOMO INCORPORATED
PS PLURALSIGHT (A)
UPWK UPWORK
CHRA CHARAH SOLUTIONS
BE BLOOM ENERGY
USX US XPRESS ENTERPRISES INC
PVH PHILLIPS-VAN HEUSEN CORPORATION
TPTX TURNING POINT THERAPEUTICS
ORGO ORGANOGENESIS HOLDINGS (A)
ATEX ANTERIX
ARCT ARCTURUS THERAPEUTICS HOLDINGS INC
ArQule to Present at the 2019 Cantor Global Healthcare Conference on O...
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 2:25 p.m. ET at the InterContinental New York Barclay in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, , under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the pr...
- Jonathan Moreland
- Jonathan Moreland
RVSB RIVERVIEW BANCORP INC.
RUN SUNRUN INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PFSW PFSWEB INC
PEI PENNSYLVANIA REAL ESTATE INVESTMENT TRUST
PBF PBF ENERGY INC. CLASS A
MCHX MARCHEX INC. CL B
LXRX LEXICON PHARMACEUTICALS INC.
IRMD IRADIMED CORP
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FATE FATE THERAPEUTICS INC
BGGSQ BRIGGS & STRATTON CORPORATION
ARQL ARQULE INC.
ALDX ALDEYRA THERAPEUTICS
SAFE SAFESTORE HOLDINGS PLC
MCF CONTANGO OIL & GAS CO.
OTEL OTELCO INC
BASI BIOANALYTICAL SYSTEMS
MOS THE MOSAIC COMPANY
FEIM FREQUENCY ELECTRONICS INC.
WOW WIDEOPENWEST INC.
ALRN AILERON THERAPEUTICS
ATNX ATHENEX
CTDH CTD HOLDINGS INC
EXPI EXP WORLD HOLDINGS
CELH CELSIUS HOLDINGS INC.
CTRA ALPHA METALLURGICAL RESOURCES INC.
ABBV ABBVIE INC.
SFIX STITCH FIX CLASS A
DXLG CASUAL MALE RETAIL GROUP,; INC.
USM UNITED STATES CELLULAR CORPORATION
KRP KIMBELL ROYALTY PARTNERS LP
KDP KEURIG DR PEPPER INC.
DBX DROPBOX INC. CLASS A
PS PLURALSIGHT (A)
UPWK UPWORK
ANIX ANIXA BIOSCIENCES
PRTS U.S. AUTO PARTS NETWORK
ORGO INC.
ATEX ORGANOGENESIS HOLDINGS (A)
RRTS ANTERIX
ROADRUNNER TRANSPORTATION SYSTEMS
- Jonathan Moreland
RVSB RIVERVIEW BANCORP INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PFSW PFSWEB INC
PBF PBF ENERGY INC. CLASS A
LXRX LEXICON PHARMACEUTICALS INC.
IRMD IRADIMED CORP
FATE FATE THERAPEUTICS INC
CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION CLASS A
ARQL ARQULE INC.
ALDX ALDEYRA THERAPEUTICS
ADRO CHINOOK THERAPEUTICS INC
SAFE SAFESTORE HOLDINGS PLC
MCF CONTANGO OIL & GAS CO.
WOW WIDEOPENWEST INC.
ZUO ZUORA
KRP KIMBELL ROYALTY PARTNERS LP
ATEX ANTERIX
RRTS ROADRUNNER TRANSPORTATION SYSTEMS
ARCT ARCTURUS THERAPEUTICS HOLDINGS INC
ArQule to Participate in the Oppenheimer Fall Summit Focused on Specia...
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on Tuesday, September 24, 2019 at The Parker New York Hotel in New York City. About ArQule ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and commercia...
- Jonathan Moreland
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
BGGSQ BRIGGS & STRATTON CORPORATION
ARQL ARQULE INC.
HIL HILL INTERNATIONAL
BASI BIOANALYTICAL SYSTEMS
MOS THE MOSAIC COMPANY
ALRN AILERON THERAPEUTICS
ATNX ATHENEX
EXPI EXP WORLD HOLDINGS
CELH CELSIUS HOLDINGS INC.
PS PLURALSIGHT (A)
CHRA CHARAH SOLUTIONS
ANIX ANIXA BIOSCIENCES
PRTS U.S. AUTO PARTS NETWORK
AMEH INC.
ORGO APOLLO MEDICAL HOLDINGS INC
ORGANOGENESIS HOLDINGS (A)
ArQule to Participate in Citi’s 14th Annual Biotech Conference on Se...
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Marc Schegerin, Chief Financial Officer, will attend Citi’s investor conference on Wednesday, September 4, 2019 at the Four Seasons Hotel in Boston, MA. In addition, Dr. Marc Schegerin will participate in the hosted panel discussion: Focusing the Laser on Precision Oncology, at 3:00 PM. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, , under “Events & Presentations.” A replay of the webcast will be ...
ArQule Reports Second Quarter 2019 Financial Results
BURLINGTON, Mass.--(BUSINESS WIRE)-- , Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2019. For the quarter ended June 30, 2019, the Company reported a net loss of $9.1 million, or $0.08 per basic share, compared with net income of $5.2 million, or $0.05 per diluted share, for the quarter ended June 30, 2018. As of June 30, 2019, the Company had a total of approximately $182.8 million in cash, cash equivalents, and marketable securities. Key Highlights from Q2, 2019 In June 2019, the Company raised approximately $104 million of gross proceeds in a ...
ArQule to Participate in the BTIG Biotechnology Conference on Monday, ...
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq:ARQL) today announced that Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will participate in the BTIG Biotechnology Conference on Monday, August 12, 2019 at The St. Regis New York in New York City. About ArQule ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve ...
ArQule to Present at the SVB Leerink Spotlight Series: Rare & Genetic ...
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases on August 8, 2019 at 9:00 a.m. ET at the The Boston Harbor Hotel in Boston, MA. About ArQule ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and commercialize novel sm...
- Jonathan Moreland
WATT ENERGOUS CORP
TPC TUTOR PERINI CORPORATION
PGNX PROGENICS PHARMACEUTICALS INC.
ONCS ONCOSEC MEDICAL
NTAP NETAPP INC.
MCHX MARCHEX INC. CL B
LB7 LIBBEY INC.
INUV INUVO INC
ESPR ESPERION THERAPEUTICS INC.
CSU CAPITAL SENIOR LIVING CORPORATION
BECN BEACON ROOFING SUPPLY INC.
ARQL ARQULE INC.
AMNB AMERICAN NATIONAL BANKSHARES INC.
VRML VERMILLION
IMMU IMMUNICUM AB
BRO BROWN & BROWN INC.
CCI CROWN CASTLE INTERNATIONAL CORP
CNFR CONIFER HOLDINGS
GEF GREIF CLASS A
THO THOR INDUSTRIES INC.
WPG WASHINGTON PRIME GROUP INC.
BXC BLUELINX HOLDINGS
AFI ARMSTRONG FLOORING INC.
UTHR UNITED THERAPEUTICS CORPORATION
ELVT ELEVATE CREDIT
CADE CADENCE BANCORPORATION
SVRA SAVARA
RIBT RICEBRAN TECHNOLOGIES
MDCO THE MEDICINES COMPANY
HTZ HERTZ GLOBAL HOLDINGS
FEIM INC.
WTI FREQUENCY ELECTRONICS INC.
ANGI W&T OFFSHORE
XELA INC.
ABBV ANGI INC. CLASS A
APLS EXELA TECHNOLOGIES INC.
AMAG ABBVIE INC.
MOTS APELLIS PHARMACEUTICALS
RCUS AMAG AUSTRIA METALL AG
EYEN MOTUS GI HOLDINGS
ZUO ARCUS BIOSCIENCES
GPS EYENOVIA INC
EB ZUORA
CFBK THE GAP
CHAP INC.
PRSP EVENTBRITE
FSLY CENTRAL FEDERAL CORP.
BPMX CHAPARRAL ENERGY
GRX INC.
KXIN PROSPERITY BANCSHARES
EFF INC.
ATEX FASTLY
PBYI BIOPHARMX
BW THE GABELLI HEALTHCARE & WELLNESSRX TRUST
KAIXIN AUTO HOLDINGS (N SHARES)
EATON VANCE FLOATING-RATE INCOME PLUS FUND
ANTERIX
INNOVATIVE ACQUISITIONS CORP
BABCOCK & WILCOX ENTERPRISES
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.